471 related articles for article (PubMed ID: 31824502)
1. Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T Cells.
Polito VA; Cristantielli R; Weber G; Del Bufalo F; Belardinilli T; Arnone CM; Petretto A; Antonucci L; Giorda E; Tumino N; Pitisci A; De Angelis B; Quintarelli C; Locatelli F; Caruana I
Front Immunol; 2019; 10():2717. PubMed ID: 31824502
[TBL] [Abstract][Full Text] [Related]
2. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies.
Deniger DC; Maiti SN; Mi T; Switzer KC; Ramachandran V; Hurton LV; Ang S; Olivares S; Rabinovich BA; Huls MH; Lee DA; Bast RC; Champlin RE; Cooper LJ
Clin Cancer Res; 2014 Nov; 20(22):5708-19. PubMed ID: 24833662
[TBL] [Abstract][Full Text] [Related]
3. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
4. Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.
Du SH; Li Z; Chen C; Tan WK; Chi Z; Kwang TW; Xu XH; Wang S
PLoS One; 2016; 11(9):e0161820. PubMed ID: 27598655
[TBL] [Abstract][Full Text] [Related]
5. Anti-metastatic potential of human Vδ1(+) γδ T cells in an orthotopic mouse xenograft model of colon carcinoma.
Devaud C; Rousseau B; Netzer S; Pitard V; Paroissin C; Khairallah C; Costet P; Moreau JF; Couillaud F; Dechanet-Merville J; Capone M
Cancer Immunol Immunother; 2013 Jul; 62(7):1199-210. PubMed ID: 23619975
[TBL] [Abstract][Full Text] [Related]
6. K562-Derived Whole-Cell Vaccine Enhances Antitumor Responses of CAR-Redirected Virus-Specific Cytotoxic T Lymphocytes In Vivo.
Caruana I; Weber G; Ballard BC; Wood MS; Savoldo B; Dotti G
Clin Cancer Res; 2015 Jul; 21(13):2952-62. PubMed ID: 25691731
[TBL] [Abstract][Full Text] [Related]
7. Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies.
Zhou J; Kang N; Cui L; Ba D; He W
Cell Mol Immunol; 2012 Jan; 9(1):34-44. PubMed ID: 21666706
[TBL] [Abstract][Full Text] [Related]
8. Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells.
Xiao L; Chen C; Li Z; Zhu S; Tay JC; Zhang X; Zha S; Zeng J; Tan WK; Liu X; Chng WJ; Wang S
Cytotherapy; 2018 Mar; 20(3):420-435. PubMed ID: 29402645
[TBL] [Abstract][Full Text] [Related]
9. Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor.
Deniger DC; Switzer K; Mi T; Maiti S; Hurton L; Singh H; Huls H; Olivares S; Lee DA; Champlin RE; Cooper LJ
Mol Ther; 2013 Mar; 21(3):638-47. PubMed ID: 23295945
[TBL] [Abstract][Full Text] [Related]
10. Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.
Mirzaei HR; Mirzaei H; Lee SY; Hadjati J; Till BG
Cancer Lett; 2016 Oct; 380(2):413-423. PubMed ID: 27392648
[TBL] [Abstract][Full Text] [Related]
11. Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood.
Kang N; Zhou J; Zhang T; Wang L; Lu F; Cui Y; Cui L; He W
Cancer Biol Ther; 2009 Aug; 8(16):1540-9. PubMed ID: 19471115
[TBL] [Abstract][Full Text] [Related]
12. Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer.
Liu Z; Eltoum IE; Guo B; Beck BH; Cloud GA; Lopez RD
J Immunol; 2008 May; 180(9):6044-53. PubMed ID: 18424725
[TBL] [Abstract][Full Text] [Related]
13. Transient stimulation expands superior antitumor T cells for adoptive therapy.
Kagoya Y; Nakatsugawa M; Ochi T; Cen Y; Guo T; Anczurowski M; Saso K; Butler MO; Hirano N
JCI Insight; 2017 Jan; 2(2):e89580. PubMed ID: 28138559
[TBL] [Abstract][Full Text] [Related]
14. The safety of allogeneic innate lymphocyte therapy for glioma patients with prior cranial irradiation.
Pereboeva L; Harkins L; Wong S; Lamb LS
Cancer Immunol Immunother; 2015 May; 64(5):551-62. PubMed ID: 25676710
[TBL] [Abstract][Full Text] [Related]
15. γδ T cells in cancer immunotherapy.
Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
[TBL] [Abstract][Full Text] [Related]
16. CMV-independent lysis of glioblastoma by ex vivo expanded/activated Vδ1+ γδ T cells.
Knight A; Arnouk H; Britt W; Gillespie GY; Cloud GA; Harkins L; Su Y; Lowdell MW; Lamb LS
PLoS One; 2013; 8(8):e68729. PubMed ID: 23950874
[TBL] [Abstract][Full Text] [Related]
17. Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.
Lynch A; Hawk W; Nylen E; Ober S; Autin P; Barber A
Immunology; 2017 Nov; 152(3):472-483. PubMed ID: 28670716
[TBL] [Abstract][Full Text] [Related]
18. γδ T Cells: The Ideal Tool for Cancer Immunotherapy.
Yazdanifar M; Barbarito G; Bertaina A; Airoldi I
Cells; 2020 May; 9(5):. PubMed ID: 32456316
[TBL] [Abstract][Full Text] [Related]
19. In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with γδ T cell immunotherapy in mice.
Hodgins NO; Al-Jamal WT; Wang JT; Parente-Pereira AC; Liu M; Maher J; Al-Jamal KT
J Control Release; 2016 Nov; 241():229-241. PubMed ID: 27664328
[TBL] [Abstract][Full Text] [Related]
20. Function of γδ T cells in tumor immunology and their application to cancer therapy.
Park JH; Lee HK
Exp Mol Med; 2021 Mar; 53(3):318-327. PubMed ID: 33707742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]